HO-1 activation can inhibit MIRI-induced inflammatory factor production during cardiopulmonary bypass and inhibit NF-κB and activator protein (AP)-1 translocation to reduce cardiomyocyte apoptosis [61], while pre-injection of HO-1 activator can significantly reduce MI infarct size and cardiomyocyte apoptosis [62]. Here, NFKB1 is linked to myocardial infarction.